ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine The...

por Burkbauer, Laura, Goldbach, Macy M., Tchou, Julia C.
Publicado 2021

Dose‐dependent effects of aerobic exercise on clinically relevant biomarkers among healthy women at high genetic risk for breast cancer: A secondary analysis of a randomized contro...

por Ehret, Christopher J., Zhou, Shouhao, Tchou, Julia C., Schmitz, Kathryn H., Sturgeon, Kathleen M.
Publicado 2021

Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)

por Goldbach, Macy M., Burkbauer, Laura, Bharani, Tina, Williams, Austin D., Keele, Luke, Rothman, Jami, Jankowitz, Rachel, Tchou, Julia C.
Publicado 2021

ASO Visual Abstract: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)

por Goldbach, Macy M., Burkbauer, Laura, Bharani, Tina, Williams, Austin D., Keele, Luke, Rothman, Jami, Jankowitz, Rachel, Tchou, Julia C.
Publicado 2021

Correction to: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)

por Goldbach, Macy M., Burkbauer, Laura, Bharani, Tina, Williams, Austin D., Keele, Luke, Rothman, Jami, Jankowitz, Rachel, Tchou, Julia C.
Publicado 2021